Sumitomo Pharma Co., Ltd. (SMPA) reported a robust financial turnaround for the fiscal year ending March 31, 2025. The company posted a net profit attributable to owners of JPY 106.9 billion, marking a record high.
Revenue for the fiscal year reached JPY 453.3 billion, a 13.7% increase year-over-year. Strong product sales in the U.S. market, particularly ORGOVYX and GEMTESA, drove this growth.
Core operating profit stood at JPY 105.9 billion, up JPY 62.8 billion from the previous year. Sumitomo's stock rose 7.74% following the earnings announcement.
For FY2026, Sumitomo forecasts revenue of JPY 540 billion and net profit of JPY 77 billion. The company is also considering resuming dividends.
CEO Kimura stated: "Our strategic initiatives have strengthened our financial base and positioned us for growth."
